Mayo Foundation for Medical Education and Research

Other

University of Minnesota

Joseph F Poduslo

Geoffrey L Curran

Geoffry L Curran

Thomas M Wengenack

Robert B Jenkins

Val J Lowe

Gobinda Sarkar

Michael G Garwood

Abdul H Fauq

Daniel J McCormick

Clifford R Jack, Jr

Erik W Mahlum

Eric W Mahlum

The peptides described herein can function as carrier peptides. These peptides can associate with (e.g., non-covalently bind) biologically active molecules or imaging agents to transport the biologically active molecules or imaging across the blood-brain barrier. In some cases, such transport may increase the effectiveness of the biological molecules or imaging agents.

Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier

Amyloid plaque in the brain of a subject is imaged in an MRI system with or without the use of a contrast agent. Contrast is achieved using a spin-echo pulse sequence that is both respiratory gated and cardiac gated to reduce motion artifacts at the very high image resolution required to see plaque. A preparatory pulse sequence is used to insure longitudinal magnetization remains constant for all the acquired views even if the effective TR changes during the scan due to irregular breathing.

Magnetic resonance imaging of amyloid plaque in the brain

Compositions that include an A&#x3b2; polypeptide linked to a non-A&#x3b2; polypeptide are described, as well as methods of using such compositions.

Treatment for central nervous system disorders

Methods for detecting parenchymal plaque deposits in the brain of a living mammal are described that include administering a polyamine modified, labeled polypeptide having specific binding affinity for the extracellular deposit, to the living mammal. Isolated &#x3b2;-amyloid peptides that are polyamine modified and labeled with a radioisotope or contrast agent also are described.

Methods for detecting parenchymal plaques in vivo

An amino acid composition with improved blood brain barrier permeability comprising an amino acid polymer, wherein the amino acid comprises at least one asparagyl-4-aminobutane or glutamyl-4-aminobutane residue.

Amino acid composition with increased blood brain barrier permeability

A method is provided to enhance the ability of a neurologically active compound to penetrate the blood nerve barrier (BNB) or blood brain barrier (BBB), by administration of a conjugate comprising the neurologically active compound linked to a carrier molecule that has been shown to have a substantial permeability coefficient across the BNB and BBB.

Method to enhance permeability of the blood/brain blood/nerve bariers to

Method to enhance permeability of the blood/brain blood/nerve barriers

A method is provided to enhance the permeability of the blood-nerve barrier or the blood-brain barrier to neuroactive proteins, comprising glycating said proteins prior to bringing them into contact with said barriers.

Growing community of inventors

Rochester, MN, United States of America

Joseph F Poduslo